Capstone Capital Management Ltd Makes New $978,000 Investment in United Therapeutics Corporation $UTHR

Capstone Capital Management Ltd purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 4th quarter, Holdings Channel reports. The firm purchased 2,008 shares of the biotechnology company’s stock, valued at approximately $978,000.

A number of other institutional investors have also made changes to their positions in the business. Profund Advisors LLC grew its position in United Therapeutics by 0.8% in the fourth quarter. Profund Advisors LLC now owns 5,288 shares of the biotechnology company’s stock valued at $2,577,000 after purchasing an additional 44 shares in the last quarter. ProShare Advisors LLC lifted its position in United Therapeutics by 2.7% during the 4th quarter. ProShare Advisors LLC now owns 3,629 shares of the biotechnology company’s stock worth $1,768,000 after buying an additional 94 shares in the last quarter. HighTower Advisors LLC boosted its stake in shares of United Therapeutics by 4.6% during the 4th quarter. HighTower Advisors LLC now owns 4,000 shares of the biotechnology company’s stock worth $1,949,000 after buying an additional 176 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in shares of United Therapeutics by 1.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,597 shares of the biotechnology company’s stock worth $1,753,000 after buying an additional 47 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $31,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 14,440 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $472.13, for a total value of $6,817,557.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the sale, the chief financial officer directly owned 18,876 shares in the company, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 530,913 shares of company stock valued at $294,807,957 over the last quarter. 8.60% of the stock is owned by corporate insiders.

United Therapeutics Stock Down 0.3%

Shares of NASDAQ:UTHR opened at $566.99 on Tuesday. The firm has a market cap of $24.07 billion, a PE ratio of 20.93, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company’s 50 day moving average price is $559.71 and its two-hundred day moving average price is $508.76.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, research analysts expect that United Therapeutics Corporation will post 27.07 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Cantor Fitzgerald increased their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.